未找到相关数据
Phase I trial of the programmed death receptor 1 (PD-1) inhibitor, BI 754091, in patients (pts) with advanced solid tumors.
被引：2
作者：
Johnson, Melissa Lynne
Patel, Manish R.
Siu, Lillian L.
Kozloff, Mark
Aljumaily, Raid
Vaishampayan, Ulka N.
Elgadi, Mabrouk M.
Ge, Miaomiao
Duffy, Christine
Graeser, Ralph
Khedkar, Sheetal Vinay
Jones, Suzanne Fields
Burris, Howard A.
机构：
[1] PLLC, Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[2] Sarah Cannon Res Inst, Florida Canc Specialists, Sarasota, FL USA
[3] Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Ingalls Mem Hosp, Harvey, IL USA
[5] Oklahoma Univ, Med Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA
[6] Karmanos Canc Ctr, Detroit, MI USA
[7] Boehringer Ingelheim GmbH & Co KG, Burlington, ON, Canada
[8] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[9] Boehringer Ingelheim Pharma GmbH & Co KG, Rhein, Germany
[10] Sarah Cannon Res Inst, Nashville, TN USA
关键词：
D O I：
10.1200/JCO.2018.36.5_suppl.212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
212
引用
收藏
页数：1
相关论文